997 results on '"Karlin, Lionel"'
Search Results
2. Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma
3. Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
4. Teclistamab in Relapsed or Refractory Multiple Myeloma
5. Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial
6. Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study
7. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma
8. Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
9. Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation
10. Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma
11. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study
12. Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies
13. Randall-Type Monoclonal Immunoglobulin Deposition Disease in Bone Scintigraphy
14. Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial.
15. HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma
16. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real‐world: The retrospective IMAGE study
17. Prediction of venous thromboembolism in patients with multiple myeloma treated with lenalidomide, bortezomib, dexamethasone, and transplantation: Lessons from the substudy of IFM/DFCI 2009 cohort
18. Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study
19. Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma
20. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study
21. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.
22. Daratumumab Carfilzomib Lenalidomide and Dexamethasone with tandem transplant in high-risk newly diagnosed myeloma
23. Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series
24. Efficacy and Safety in Patients with Lenalidomide-Refractory Multiple Myeloma and 1–3 Prior Lines Who Received a Single Infusion of Ciltacabtagene Autoleucel As Study Treatment in the Phase 3 Cartitude-4 Trial
25. Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
26. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial
27. Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified
28. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
29. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
30. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis
31. Results of a nation-wide cohort study suggest favorable long-term outcomes of clone-targeted chemotherapy in immunotactoid glomerulopathy
32. Evaluation of participation and recruitment bias in a prospective Real World Data in Lymphoma and Survival in Adults (REALYSA) cohort for newly diagnosed lymphoma patients over 1 year in a hematology department of teaching hospital.
33. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
34. The EMMY Longitudinal, Cohort Study: Real-World Data to Describe Multiple Myeloma Management and Outcomes as More Therapeutic Options Emerge
35. Low non‐relapse mortality and good haematological and renal responses after autologous haematopoietic stem cell transplantation in multiple myeloma patients with renal insufficiency at transplant: A prospective Société Francophone de Greffe de Moelle‐Thérapie Cellulaire observational study
36. Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study
37. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
38. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
39. Thrombin generation in newly diagnosed multiple myeloma during the first three cycles of treatment: An observational cohort study
40. Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma
41. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
42. Low non‐relapse mortality and good haematological and renal responses after autologous haematopoietic stem cell transplantation in multiple myeloma patients with renal insufficiency at transplant: A prospective Société Francophone de Greffe de Moelle‐Thérapie Cellulaire observational study
43. Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.
44. POSTER: MM-374 Efficacy and Safety of Elranatamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Prior B-Cell Maturation Antigen (BCMA)- Directed Therapies: Pooled Analysis From MagnetisMM Studies
45. P-325 Standard of care (SOC) outcomes in the last 3 years in patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM): the first pooled analysis of LocoMMotion and MoMMent trials
46. MM-374 Efficacy and Safety of Elranatamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Prior B-Cell Maturation Antigen (BCMA)-Directed Therapies: Pooled Analysis From MagnetisMM Studies
47. P-287 Isatuximab plus pomalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma in real life context in France: IMAGE subgroup analysis based on subgroups of interest
48. P-302 Anchor (OP-104): melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/ refractory multiple myeloma (RRMM) – final efficacy and safety results
49. MM-162 Durability of Responses With Biweekly Dosing of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma Achieving a Clinical Response in the MajesTEC-1 Study
50. POSTER: MM-162 Durability of Responses With Biweekly Dosing of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma Achieving a Clinical Response in the MajesTEC-1 Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.